SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dark storm clouds. Soft evening light breaks through the clouds, creating an atmosphere of waiting for the storm in the image. Perfect photo for nature, climate, weather, drama and emotional background concepts.
Autoimmune diseases
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
October 23, 2026
 · 
2 min read
 · 
Heather McKenzie
Business woman pushing big ball. concept of difficulty, ambition, motivation, struggle
Huntington’s disease
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.
October 23, 2026
 · 
3 min read
 · 
Annalee Armstrong
Red trend as symbol of economy drop or financial crisis. Business pattern
Pancreatic cancer
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.
October 23, 2026
 · 
4 min read
 · 
Heather McKenzie
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Tango plans 14% workforce cut, mainly of research staff
Follow along as BioSpace tracks job cuts and restructuring initiatives.
October 23, 2026
 · 
107 min read
 · 
BioSpace Editorial Staff
German flags waving in the wind at famous Reichstag building, seat of the German Parliament (Deutscher Bundestag), on a sunny day with blue sky and clouds, central Berlin Mitte district, Germany.
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
October 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Perspective view of supermarket aisle. Supermarket with colorful shelves of merchandise and front door and supermarket food cart. Cartoon vector illustration
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.
October 23, 2026
 · 
1 min read
 · 
Annalee Armstrong
Intricate vector illustration of vibrant cancer cells on a blue grid, highlighting microscopic detail.
Immuno-oncology
ESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2
Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor therapy.
October 23, 2026
 · 
3 min read
 · 
Michael Gibney
3d sketch poster trend collage image of hands hold chess figurine knight queen rival china america trade war economic problem.
China
US explores China biotech restrictions, exempts licensing deals
A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security drew cautious statements from across the industry, with leaders vowing to ensure innovation isn’t stifled.
October 23, 2026
 · 
3 min read
aardvark walking in the desert
FDA
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
October 23, 2026
 · 
3 min read
 · 
Tristan Manalac
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS